Lumos Pharma (LUMO) Competitors $4.34 0.00 (0.00%) (As of 12/12/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUMO vs. PBYI, TIL, ELUT, BDTX, GALT, TELO, CGEN, JATT, ENTA, and MNPRShould you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Puma Biotechnology (PBYI), Instil Bio (TIL), Elutia (ELUT), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Telomir Pharmaceuticals (TELO), Compugen (CGEN), JATT Acquisition (JATT), Enanta Pharmaceuticals (ENTA), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Lumos Pharma vs. Puma Biotechnology Instil Bio Elutia Black Diamond Therapeutics Galectin Therapeutics Telomir Pharmaceuticals Compugen JATT Acquisition Enanta Pharmaceuticals Monopar Therapeutics Puma Biotechnology (NASDAQ:PBYI) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation. Is PBYI or LUMO more profitable? Puma Biotechnology has a net margin of 9.56% compared to Lumos Pharma's net margin of -1,583.49%. Puma Biotechnology's return on equity of 41.60% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Lumos Pharma -1,583.49%-233.03%-129.88% Does the MarketBeat Community believe in PBYI or LUMO? Puma Biotechnology received 513 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 75.51% of users gave Lumos Pharma an outperform vote while only 67.07% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55067.07% Underperform Votes27032.93% Lumos PharmaOutperform Votes3775.51% Underperform Votes1224.49% Does the media prefer PBYI or LUMO? In the previous week, Puma Biotechnology had 1 more articles in the media than Lumos Pharma. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for Lumos Pharma. Puma Biotechnology's average media sentiment score of 1.45 beat Lumos Pharma's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Puma Biotechnology Positive Lumos Pharma Neutral Do institutionals and insiders believe in PBYI or LUMO? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, PBYI or LUMO? Puma Biotechnology has higher revenue and earnings than Lumos Pharma. Lumos Pharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$243.57M0.55$21.59M$0.485.73Lumos Pharma$2.21M17.02-$34.03M-$4.29-1.01 Which has more risk and volatility, PBYI or LUMO? Puma Biotechnology has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Do analysts recommend PBYI or LUMO? Puma Biotechnology presently has a consensus target price of $7.00, suggesting a potential upside of 154.55%. Lumos Pharma has a consensus target price of $8.63, suggesting a potential upside of 98.73%. Given Puma Biotechnology's higher probable upside, research analysts plainly believe Puma Biotechnology is more favorable than Lumos Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lumos Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryPuma Biotechnology beats Lumos Pharma on 13 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Lumos Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUMO vs. The Competition Export to ExcelMetricLumos PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.54M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-1.0110.4289.5817.17Price / Sales17.02195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book1.265.094.774.78Net Income-$34.03M$151.83M$120.15M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month Performance0.23%-3.10%11.47%3.36%1 Year Performance45.64%11.54%30.54%16.60% Lumos Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUMOLumos Pharma3.0946 of 5 stars$4.34flat$8.63+98.7%+44.2%$37.54M$2.21M-1.0130High Trading VolumePBYIPuma Biotechnology3.9481 of 5 stars$3.02+4.9%$7.00+131.8%-30.0%$148.25M$243.57M6.42185Positive NewsTILInstil Bio2.8565 of 5 stars$22.28+1.4%$145.00+550.8%+196.5%$145.40MN/A-1.9149ELUTElutia2.7375 of 5 stars$4.19+1.2%$10.00+138.7%+148.2%$144.81M$24.75M-1.59180BDTXBlack Diamond Therapeutics2.361 of 5 stars$2.54-0.8%$15.50+510.2%-16.2%$143.73MN/A-1.9290Positive NewsGap DownGALTGalectin Therapeutics1.9706 of 5 stars$2.29+8.3%$11.00+381.4%-39.2%$143.41MN/A-3.149News CoverageGap DownHigh Trading VolumeTELOTelomir PharmaceuticalsN/A$4.80-7.7%N/AN/A$142.13MN/A0.001High Trading VolumeCGENCompugen1.5938 of 5 stars$1.59-1.6%$4.00+152.4%-17.3%$141.44M$59.85M80.5068JATTJATT AcquisitionN/A$8.16-24.1%N/A-51.6%$140.76MN/A0.003High Trading VolumeENTAEnanta Pharmaceuticals4.0469 of 5 stars$6.50+7.8%$19.50+200.0%-26.3%$137.76M$67.64M-1.10145MNPRMonopar Therapeutics1.9712 of 5 stars$26.05+2.6%$27.33+4.9%+1,165.4%$137.49MN/A-12.8810News Coverage Related Companies and Tools Related Companies Puma Biotechnology Competitors Instil Bio Competitors Elutia Competitors Black Diamond Therapeutics Competitors Galectin Therapeutics Competitors Telomir Pharmaceuticals Competitors Compugen Competitors JATT Acquisition Competitors Enanta Pharmaceuticals Competitors Monopar Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUMO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
